title: Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia.
authors.affiliation: Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, 33612, USA; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Electronic address: Mohamed.Kharfan-Dabaja@Moffitt.org.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Kharfan-Dabaja
authors.affiliation: Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, 33612, USA; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
authors.forename: Taiga
authors.initials: T
authors.lastname: Nishihori
authors.affiliation: Department of Internal Medicine and Bone Marrow Transplantation Program, American University of Beirut, Beirut, Lebanon.
authors.forename: Ali
authors.initials: A
authors.lastname: Bazarbachi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000601:surgery*; D008297:Male; D019172:Transplantation Conditioning; D014740:Vidarabine / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D014740:Vidarabine; D002066:Busulfan